Evidence map›Paper›PMID 40830977›Full record

ArticleOrphanet journal of rare diseases2025

Development of a conceptual model of early systemic sclerosis (scleroderma).

William R Lenderking, Mary Kathleen Ladd, Nicola Barnes, Julia Braverman, Maria Gasior, Jutta Hofmann, John-Phillip Lawo, Dinesh Khanna

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

William R LenderkingPPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Waltham, MA, USA.
Mary Kathleen LaddPPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Waltham, MA, USA. MaryKate.Ladd@thermofisher.com.ORCID 0009-0005-1755-6210
Nicola BarnesPPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, England.
Julia BravermanCSL Behring, King of Prussia, PA, USA.
Maria GasiorCSL Behring, King of Prussia, PA, USA.
Jutta HofmannCSL Innovation GmbH, Marburg, Germany.
John-Phillip LawoCSL Innovation GmbH, Marburg, Germany.
Dinesh KhannaUniversity of Michigan, Ann Arbor, MI, USA.

Funding

CSL Behring
6 · The paper itself

Abstract

backgroundSystemic sclerosis (SSc) is a rare connective tissue disorder with heterogeneous manifestations. Two predominant subtypes, limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc), are distinguished based on skin involvement distribution. A comprehensive conceptual SSc model is needed to support measurement strategies for outcome studies. This qualitative study aimed to explore key SSc disease concepts and develop a conceptual disease model capturing the heterogeneous lived experiences of patients with SSc.

methodsPatient- and clinician-reported concepts specific to dcSSc (more severe and faster-progressing than lcSSc) were identified via a targeted literature review and used to develop a preliminary dcSSc symptom model and a semi-structured qualitative interview guide. The guide was used in concept elicitation interviews with adults with lcSSc and dcSSc. A final conceptual SSc symptoms model was refined based on interview results.

resultsDisease concepts were retrieved from 35 peer-reviewed articles and 17 clinical trials focusing on patients with dcSSc. The preliminary dcSSc symptom model included skin, hand, gastrointestinal, pain, joint, muscle, mouth, sexual, lung, cardiovascular, cognitive, ocular, and other symptoms. During concept elicitation interviews, participants (n = 44) reported 112 unique symptoms (within 13 domains). Twenty-six symptoms had not previously been identified in pertinent literature. Hand and skin symptoms were reported by all participants. Over 95% of participants reported at least one gastrointestinal and pain symptom, around 80% reported joint and mouth symptoms, 70% reported muscle symptoms, and over 50% reported ocular symptoms. Cognitive, lung, sexual, and cardiac symptoms were reported by fewer than half of participants. Participants with dcSSc reported a broader variety of symptoms than those with lcSSc. However, concepts relevant to patients with dcSSc and lcSSc strongly overlapped, suggesting that a single conceptual model is appropriate to map symptoms for both subtypes. The overlap was further reflected in the most bothersome symptoms, which included skin fibrosis and hand symptoms for both populations.

conclusionsThe final conceptual model captures the heterogeneous symptoms of SSc and reflects the lived experience of patients with SSc. It covers both clinical SSc subtypes and can support the choice and/or development of instruments to measure patient experiences in clinical trials.

Indexed as

Scleroderma, SystemicAdultAgedFemaleHumansMaleMiddle AgedConcept elicitation interviewsConceptual disease modelCutaneous systemic sclerosisPhysical symptomsQualitative researchScleroderma

Identifiers

PMID40830977
PMCPMC12366407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.